Background: Characteristics and research collaboration of registered systematic reviews (SRs) on treatment for coronavirus disease 2019 (COVID-19) remain unclear. This study aimed to analyze research collaboration, interventions, and outcome measures in registered SRs of treatment associated with COVID-19 and point out the problem.Methods: PROSPERO was searched for SRs of treatment related to COVID-19 as of June 2, 2020. Excel 2016 was used for descriptive statistical analysis of the extracted

more »

... nformation. VOSviewer 1.6.14 software was used to generate network maps for collaborations between countries and institutions.Results: A total of 189 SRs were included, which were registered by 301 institutions from 39 countries. China (69, 36.50%) was the country with the highest output. Cooperation between countries was not close enough. Chengdu university of traditional Chinese medicine (7, 3.70%) was the institutions with the highest output. There is close cooperation between institutions. Interventions included antiviral therapy (81, 42.86%), respiratory support (16, 8.47%), circulation support (11, 5.82%), plasma therapy for convalescent patients (11, 5.82%), immunotherapy (9, 4.76%), TCM Treatment (9, 4.76%), rehabilitation treatment (5, 2.65%), anti-inflammatory treatment (16, 8.47%), and other treatments (31, 16.40%). In antiviral therapy (81, 42.86%), the most commonly used drugs were chloroquine/hydroxychloroquine (26, 13.76%), followed by remdesivir (12, 6.35%), lobinavir/ritonavir(11, 5.82%), favipiravir (5, 2.65%), ribavirin (5, 2.65%), interferon (5, 2.65%), abiron (4, 2.12%), abidor (4, 2.12%), but the description was brief, and no specific implementation plan was provided. The most frequently used primary outcome was mortality rate (92, 48.68%), and the most frequently used secondary outcome was length of hospital stay (48, 25.40%). The expression of the outcomes was not standardized.Conclusions: Many COVID-19 SRs of treatment have been registered, but the completion rate was low. Although there were some collaborations between countries and institutions of the current registered SRs of treatment related to COVID-19 on PROSPERO, cooperation between countries should be further strengthened. More attention should be paid to the deficiency of interventions and outcome measures, and the standardization of results should be strengthened.